DenCe-ctive – Use of autologous Thrombocytes

The therapeutic use of dendritic cells in vaccination

therapy requires prior activation of these immune cells. The invention exploits the ability of stimulated thrombocytes to activate dendritic cells ex vivo thereby offering the unique possibility of autologous activation. Commercial Opportunities Immune therapy using activated dendritic cells is a well established approach used for various therapies including cancer vaccination strategies. An enormous market potential is expected. The invention provides the first method triggering an autologous maturation of dendritic cells into potent antigen presenting cells. Thus, the method constitutes a highly efficacious approach for inducing T-cell responses. The simple and efficient activation strategy is strikingly easy to handle and compatible with established immunotherapy protocols.

Weitere Informationen: PDF

PROvendis GmbH
Tel.: +49 (0)208/94105 10

Ansprechpartner
Dipl.-Ing. Alfred Schillert